Literature DB >> 15188165

Are claims of equivalency in digestive diseases trials supported by the evidence?

Jill M Tinmouth1, Leah S Steele, George Tomlinson, Richard H Glazier.   

Abstract

BACKGROUND & AIMS: Traditionally, randomized controlled trials (RCTs) have attempted to show the superiority of one intervention over another. However, when effective treatment already exists, it is sometimes more useful to prove that an intervention is equivalent, or at least not inferior, to the standard of care. Our aim was to determine whether claims of equivalency in digestive diseases trials are supported by the evidence.
METHODS: Medline was searched for RCTs published between 1989 and 2002 using the MeSH headings "exp therapeutic equivalency" and "exp digestive diseases" and the text words "equivalence," "equal," "equals," or "equivalent," yielding 902 articles. Of these, 73 articles met the inclusion criteria. These articles were evaluated using previously published criteria for equivalency.
RESULTS: Of the included articles, 33% stated an a priori research aim of equivalency, 92% reported differences of <20% between "equal" interventions, 34% set an equivalency boundary and tested it appropriately, and 19% performed a sample size calculation for equivalency. Overall, 12% of the reviewed articles met all 5 criteria. Fifty-two percent of our sample inappropriately used a failed superiority test (i.e., a P value > 0.05) as statistical "proof" of equivalency. Nonsurgical trials and those published between 1996 and 2002 were more likely to meet criteria than were surgical trials (P = 0.07) or trials published before 1996 (P = 0.003).
CONCLUSIONS: Claims of equivalency between interventions in digestive diseases trials tend to be poorly supported by the evidence. Erroneous claims of equivalency are potentially dangerous and may lead to substandard patient care.

Entities:  

Mesh:

Year:  2004        PMID: 15188165     DOI: 10.1053/j.gastro.2004.03.005

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

Review 1.  Treatment of uncomplicated reflux disease.

Authors:  Joachim Labenz; Peter Malfertheiner
Journal:  World J Gastroenterol       Date:  2005-07-28       Impact factor: 5.742

Review 2.  How to critically appraise an article.

Authors:  Jane M Young; Michael J Solomon
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2009-01-20

3.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

Review 4.  Optimising acid inhibition treatment.

Authors:  Fernando Gomollón; Xavier Calvet
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  [The ABC's of medical statistics. Reading and understanding clinical trials].

Authors:  J Labenz; C U Kunz
Journal:  Internist (Berl)       Date:  2010-04       Impact factor: 0.743

6.  Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.

Authors:  Oghenowede Eyawo; Chia-Wen Lee; Beth Rachlis; Edward J Mills
Journal:  Trials       Date:  2008-12-03       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.